| ISIN | LU1540962054 |
|---|---|
| Valor Number | 35004489 |
| Bloomberg Global ID | |
| Fund Name | HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund P USD Cap |
| Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
| Fund Provider | HBM Partners AG |
| Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
| Distributor(s) | FundPartner Solutions (Suisse) S.A. |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
| Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
| Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
| Peculiarities |
| Current Price * | 596.01 USD | 30.10.2025 |
|---|---|---|
| Previous Price * | 593.36 USD | 29.10.2025 |
| 52 Week High * | 596.01 USD | 30.10.2025 |
| 52 Week Low * | 392.02 USD | 08.04.2025 |
| NAV * | 596.01 USD | 30.10.2025 |
| Issue Price * | 596.01 USD | 30.10.2025 |
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 22,582,511 | |
| Unit/Share Assets *** | 18,533,994 | |
| Trading Information SIX | ||
| YTD Performance | +29.07% |
31.12.2024 - 30.10.2025
31.12.2024 30.10.2025 |
|---|---|---|
| YTD Performance (in CHF) | +13.97% |
31.12.2024 - 30.10.2025
31.12.2024 30.10.2025 |
| 1 month | +7.72% |
30.09.2025 - 30.10.2025
30.09.2025 30.10.2025 |
| 3 months | +27.81% |
30.07.2025 - 30.10.2025
30.07.2025 30.10.2025 |
| 6 months | +30.76% |
30.04.2025 - 30.10.2025
30.04.2025 30.10.2025 |
| 1 year | +19.87% |
30.10.2024 - 30.10.2025
30.10.2024 30.10.2025 |
| 2 years | +65.98% |
30.10.2023 - 30.10.2025
30.10.2023 30.10.2025 |
| 3 years | +52.36% |
31.10.2022 - 30.10.2025
31.10.2022 30.10.2025 |
| 5 years | +38.83% |
30.10.2020 - 30.10.2025
30.10.2020 30.10.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| argenx SE ADR | 6.55% | |
|---|---|---|
| Merus NV | 6.27% | |
| Madrigal Pharmaceuticals Inc | 5.09% | |
| Alnylam Pharmaceuticals Inc | 5.06% | |
| Xenon Pharmaceuticals Inc | 4.46% | |
| Ascendis Pharma AS ADR | 4.41% | |
| PTC Therapeutics Inc | 3.41% | |
| Genmab AS | 3.36% | |
| Scholar Rock Holding Corp | 3.31% | |
| Insmed Inc | 3.20% | |
| Last data update | 30.09.2025 | |
| TER | 0.0133% |
|---|---|
| TER date | 31.01.2018 |
| Performance Fee *** | 15.00% |
| PTR | |
| Max. Management Fee *** | 1.10% |
| Ongoing Charges *** | 2.51% |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |